Healthy Skepticism Library item: 6571

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Rhône-Poulenc Rorer claims Orudis SR has “high GI tolerance” and “can provide your arthritis patients with another dimension in pain relief”
MaLAM Australian News 1995 Feb; 3:(2):1-2

Abstract:

In order to improve compliance Rhone-Poulenc Rorer has developed a once daily version of ketoprofen (Orudis SR). However, there is theoretical evidence and also some evidence from case control studies that Orudis SR may not be as safe as Orudis.

Keywords:
*analysis/Australia/developed countries/ketoprofen/Orudis SR/Rhone-Poulenc/ NSAID/ nonsteroidal anti-inflammatory drugs/safety & risk information/MaLAM/Medical Lobby for Appropriate Marketing/EVALUATION OF PROMOTION: DRUG SAFETY/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPED COUNTRIES